Last updated: August 26, 2026
ISOVUE-M 200 is a legacy, iodinated contrast medium containing iopamidol at 200 mg iodine/mL for intrathecal administration. Bracco Diagnostics markets the product in the United States. Its commercial trajectory is driven by procedure volume, hospital purchasing, generic competition, supply reliability, and substitution with other low-osmolar contrast agents rather than by patent exclusivity. Public filings do not disclose standalone ISOVUE-M 200 sales, margins, or product-level forecasts.
What is ISOVUE-M 200 and how is it used?
ISOVUE-M 200 is an injectable solution of iopamidol, a nonionic, low-osmolar iodinated contrast agent. The "200" designation refers to its iodine concentration of 200 mg iodine/mL. The product is intended for intrathecal imaging procedures, including myelography and contrast-enhanced computed tomography of the spine and subarachnoid space, subject to the FDA-approved labeling.[1]
| Attribute |
ISOVUE-M 200 |
| Active ingredient |
Iopamidol |
| Concentration |
200 mg iodine/mL |
| Dosage form |
Sterile injectable solution |
| Route |
Intrathecal |
| Drug class |
Nonionic, low-osmolar iodinated contrast medium |
| U.S. manufacturer |
Bracco Diagnostics Inc. |
| Regulatory status |
FDA-approved prescription drug |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
| Primary customers |
Hospitals, imaging centers, radiology departments |
| Main demand driver |
Myelography and related neuroradiology procedures |
The product competes in a procedure-based market. Demand depends on the number of eligible imaging procedures, physician preference, formulary decisions, and availability of equivalent or substitutable contrast agents.
What is the FDA regulatory status of ISOVUE-M 200?
ISOVUE-M 200 is an FDA-approved product under Bracco's iopamidol product family. FDA labeling identifies iopamidol injection as a prescription diagnostic radiopaque agent. The product is subject to postmarketing safety requirements related to hypersensitivity reactions, seizures, neurotoxicity, renal risk, and other adverse events associated with iodinated contrast media.[1]
The product is chemically synthesized and administered as a drug-device combination in clinical use, although its core regulatory status is that of a prescription pharmaceutical. It does not receive biologic exclusivity, and biosimilar competition is irrelevant.
FDA exclusivity and regulatory protection
ISOVUE-M 200 is a mature product. Its original approval dates to the early commercial period for iopamidol-based contrast media. Any original new-drug exclusivity and patent protection associated with launch would have expired long ago.
The current commercial protection is therefore based on:
- FDA-approved labeling and physician familiarity.
- Manufacturing scale and sterile injectable capability.
- Hospital contracts and group purchasing arrangements.
- Brand recognition within radiology departments.
- Supply continuity.
- Regulatory and quality systems.
- Potential product-specific manufacturing know-how.
These protections are weaker than active patent exclusivity. They can preserve market share but do not prevent approved generic or alternative contrast products from competing.
What patents protect ISOVUE-M 200?
No active, commercially meaningful patent protection is apparent from the product's age and regulatory history. The original composition and use patents for iopamidol-based contrast media would have expired before the current market period.
The likely intellectual-property position is:
| Protection category |
Current commercial relevance |
| Original iopamidol composition patents |
Expired |
| Original method-of-use patents |
Expired or commercially obsolete |
| Product formulation patents |
Limited relevance; no publicly established blocking patent identified |
| Manufacturing process patents |
Possible, but generally difficult to use against an approved competing product without infringement-specific facts |
| Trade secrets |
Potentially relevant to process yield, impurity control, sterilization, and packaging |
| Trademark protection |
Brand protection for ISOVUE and ISOVUE-M |
| FDA approval barrier |
Remains relevant for new entrants but does not create exclusivity |
The absence of effective patent exclusivity means that the principal barrier is not legal exclusion. It is the cost and complexity of producing a sterile injectable at commercial scale while satisfying FDA quality requirements.
When does ISOVUE-M 200 lose exclusivity?
ISOVUE-M 200 has already lost traditional market exclusivity. It is a mature contrast medium rather than a protected growth product.
The practical exclusivity timeline is:
| Period |
Commercial position |
| Original launch period |
Protected by new-drug approval, early market development, and likely patent rights |
| Post-patent period |
Entry became legally possible through generic or alternative iopamidol products |
| Current period |
Brand value depends on procurement, availability, clinical familiarity, and supply reliability |
The product's age also limits the strategic value of patent litigation. A manufacturer challenging an old contrast agent would generally focus on FDA approval and commercial substitution rather than a high-value Paragraph IV campaign.
Are there Paragraph IV challenges against ISOVUE-M 200?
A high-profile, current Paragraph IV challenge against ISOVUE-M 200 is not a major feature of its market profile. Paragraph IV litigation is most commercially significant before or near the end of patent exclusivity for high-revenue drugs. ISOVUE-M 200 is a mature injectable diagnostic product with no publicly established blocking patent estate of comparable importance.
Generic applicants for iopamidol products would generally rely on an abbreviated new drug application, where applicable, and address pharmaceutical equivalence, sterility, strength, quality, and labeling requirements. The economic incentive to litigate depends on expected contract access and manufacturing economics rather than the value of a large branded patent franchise.
What generic and competitive products challenge ISOVUE-M 200?
ISOVUE-M 200 faces competition from two sources: iopamidol-equivalent products and clinically substitutable contrast agents.
Direct competition
Direct competition includes other iopamidol injections at comparable concentrations and approved routes. Generic iopamidol can compete on price if it secures FDA approval, reliable supply, and hospital purchasing access.
Therapeutic and procedural substitutes
The broader competitive set includes:
| Product or ingredient |
Company or supplier group |
Competitive relationship |
| Omnipaque, iohexol |
GE HealthCare and generic suppliers |
Major alternative nonionic contrast agent |
| Visipaque, iodixanol |
GE HealthCare |
Low-osmolar or iso-osmolar alternative, depending on procedure |
| Optiray, ioversol |
Guerbet |
Competing iodinated contrast medium |
| Generic iopamidol |
Multiple injectable-drug manufacturers |
Direct price and formulary competitor |
| Other approved intrathecal agents |
Multiple suppliers |
Procedure-specific substitutes |
Clinical substitution is constrained by the approved route, concentration, physician preference, institutional protocols, and product availability. A hospital may switch among contrast agents during a shortage, contract reset, or formulary review, but such changes require operational and clinical controls.
What formulations are protected by ISOVUE-M 200?
ISOVUE-M 200 is differentiated by concentration and route rather than by a currently enforceable proprietary formulation patent. The 200 mg iodine/mL concentration is relevant to intrathecal dosing and imaging protocols.
Commercially relevant formulation attributes include:
- Iopamidol concentration.
- Osmolality and viscosity.
- Sterility and endotoxin control.
- Container-closure integrity.
- Compatibility with clinical administration procedures.
- Labeling for intrathecal use.
- Stability during storage and handling.
These attributes create quality and regulatory requirements. They do not necessarily create patent barriers.
How strong is the ISOVUE-M 200 patent estate?
The patent estate is weak as a current exclusivity instrument and stronger as a historical brand and manufacturing platform.
| Factor |
Assessment |
| Patent life |
Expired or non-blocking for current commercial purposes |
| Regulatory exclusivity |
Expired |
| Formulation moat |
Limited |
| Manufacturing barrier |
Moderate to high |
| Brand and clinical familiarity |
Moderate |
| Hospital procurement position |
Contract-dependent |
| Generic launch exposure |
Moderate |
| Substitution exposure |
Moderate to high |
| Litigation value |
Low relative to protected specialty drugs |
The principal defensibility is operational. Sterile contrast media require validated manufacturing, quality controls, reliable raw materials, FDA compliance, and distribution capacity. These requirements can delay new entrants, but they do not prevent competition indefinitely.
How does ISOVUE-M 200 compare with competing contrast agents?
ISOVUE-M 200 has a narrower indication and lower strategic importance than broad hospital contrast brands such as Omnipaque and Visipaque. It benefits from specialization in intrathecal use but has less opportunity to capture demand across the full range of CT, angiography, and other radiologic procedures.
| Dimension |
ISOVUE-M 200 |
Omnipaque |
Visipaque |
| Active ingredient |
Iopamidol |
Iohexol |
Iodixanol |
| Primary commercial position |
Intrathecal and other labeled imaging uses within the Isovue family |
Broad hospital imaging use |
Broad imaging use with iso-osmolar positioning |
| Brand owner |
Bracco |
GE HealthCare |
GE HealthCare |
| Market maturity |
Mature |
Mature |
Mature |
| Patent-driven pricing power |
Low |
Low to moderate by presentation and market |
Low to moderate by presentation and market |
| Main commercial risk |
Generic substitution and procedure volume |
Hospital contracts and supply |
Price, supply, and formulary competition |
What are the market dynamics for ISOVUE-M 200?
The market is mature, price-sensitive, and procurement-driven. The principal dynamics are:
Procedure volume
Demand tracks the number of myelography and related neuroradiology procedures. Growth is limited by the mature nature of these procedures and by substitution toward other imaging approaches where clinically appropriate.
Hospital purchasing
Hospitals and group purchasing organizations negotiate contrast media contracts. Price, availability, rebates, shipping reliability, and portfolio breadth often matter as much as brand preference.
Supply-chain resilience
Iodinated contrast media have experienced supply disruptions across the industry. Manufacturing interruptions, raw-material constraints, sterilization capacity, and distribution bottlenecks can shift demand rapidly among suppliers. A reliable supplier can retain or gain accounts even without patent protection.
Generic pressure
Generic iopamidol creates direct price pressure. The impact is greatest where hospitals treat contrast media as interchangeable commodities. The impact is lower where clinicians prefer a specific product, contracts bundle multiple presentations, or generic supply is inconsistent.
Clinical switching costs
Switching is feasible but not frictionless. Hospitals must evaluate labeling, concentration, administration protocols, pharmacy and radiology workflows, inventory, and adverse-event procedures. These factors can protect an incumbent brand from immediate displacement.
What is the financial trajectory of ISOVUE-M 200?
Standalone revenue for ISOVUE-M 200 is not publicly disclosed. Bracco is privately held, and its public corporate information does not provide audited product-level sales for individual Isovue presentations. Any precise revenue estimate for ISOVUE-M 200 would therefore be speculative.
The financial trajectory is best characterized as follows:
| Financial factor |
Expected effect |
| Unit pricing |
Downward pressure from generic and contract competition |
| Volume |
Stable to modest, tied to procedure activity |
| Gross margin |
Supported by sterile manufacturing but pressured by procurement |
| Revenue growth |
Limited without procedure growth or share gains |
| Cash generation |
Potentially stable because the product is mature and established |
| R&D burden |
Low compared with innovative therapeutics |
| Commercial investment |
Focused on supply, contracts, regulatory compliance, and portfolio management |
| Upside |
Share gains during shortages, bundled contracts, or supply disruptions at competitors |
| Downside |
Generic substitution, declining myelography volumes, and loss of hospital contracts |
ISOVUE-M 200 is likely a maintenance and cash-generation product rather than a major growth asset. Its value comes from recurring institutional demand and its position within Bracco's broader contrast-media portfolio. The product may also benefit from portfolio economics: hospitals purchasing multiple Isovue concentrations or related Bracco products can reduce the impact of low standalone margins on one presentation.
What generic launch risks exist for ISOVUE-M 200?
The main generic-launch risks are commercial rather than patent-related.
A generic entrant must establish:
- FDA approval for the relevant strength, route, and presentation.
- Validated sterile manufacturing capacity.
- Reliable supply of iopamidol and packaging components.
- Hospital and group-purchasing contracts.
- Distribution coverage.
- Pharmacovigilance and product-quality support.
A low-cost entrant can pressure price quickly if it supplies major accounts. A supply-constrained entrant may have limited market impact even after approval. The most realistic launch scenario is gradual account penetration through tenders and distributor contracts, followed by price competition in commoditized hospital channels.
What litigation and settlement issues affect ISOVUE-M 200?
No material, product-defining patent litigation or settlement framework is central to the current commercial position of ISOVUE-M 200. Because the product's primary exclusivity period is historical, the important legal issues are more likely to involve:
- FDA compliance and manufacturing quality.
- Product liability.
- Distribution and supply contracts.
- Hospital procurement disputes.
- Patent disputes over specific manufacturing processes, if asserted.
- Trademark or labeling matters.
A conventional first-filer Paragraph IV settlement is unlikely to be the main determinant of market timing for this mature product.
What geographic markets matter for ISOVUE-M 200?
The United States is commercially important because of its hospital purchasing system, FDA requirements, and established contrast-media market. Outside the United States, the competitive position depends on national approvals, tenders, reimbursement, distributor relationships, and local generic penetration.
Bracco has an international contrast-media business, but the economics of an individual 200 mg iodine/mL presentation vary by country. European and other markets may use different brand names, pack sizes, procurement rules, and regulatory classifications.
Key Takeaways
- ISOVUE-M 200 is a mature iopamidol contrast agent for intrathecal use.
- Its original patent and regulatory exclusivity are no longer the main commercial protections.
- Public sources do not disclose standalone revenue or margin data.
- Market performance depends on imaging volume, hospital contracts, generic supply, and manufacturing reliability.
- The product faces direct competition from generic iopamidol and substitution from iohexol, iodixanol, ioversol, and other iodinated contrast agents.
- Sterile injectable manufacturing and supply reliability are more important barriers than active patents.
- The likely financial profile is stable or declining revenue with recurring cash generation, rather than high-growth expansion.
- Biosimilar risk is not applicable because ISOVUE-M 200 is a chemically synthesized drug.
- Generic entry risk is moderate, but actual price erosion depends on FDA-approved supply and hospital contract access.
FAQs
Is ISOVUE-M 200 the same as iopamidol?
Yes. ISOVUE-M 200 is a branded iopamidol injection containing 200 mg iodine/mL.
Can ISOVUE-M 200 be replaced by Omnipaque?
Potential substitution depends on the procedure, approved route, concentration, institutional protocol, and physician judgment. Omnipaque contains iohexol rather than iopamidol.
Is ISOVUE-M 200 listed in the Orange Book?
The relevant FDA listing must be evaluated by the applicable NDA, strength, and marketing status. As a mature product, it should not be assumed to have active patent exclusivity merely because it remains marketed.
Does ISOVUE-M 200 have biosimilar competition?
No. Biosimilars apply to biological products. ISOVUE-M 200 is a chemically synthesized iodinated contrast drug.
What is the main investment risk for ISOVUE-M 200?
The main risks are generic price pressure, hospital contract losses, reduced procedure volumes, and supply-chain disruption. Patent expiry is a historical issue rather than the primary current risk.
References
-
U.S. Food and Drug Administration. (n.d.). ISOVUE-M (iopamidol injection) prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Library of Medicine. (n.d.). DailyMed: Iopamidol injection labeling. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Bracco Diagnostics Inc. (n.d.). ISOVUE product information. Bracco. https://www.bracco.com/
-
U.S. Food and Drug Administration. (n.d.). Drug shortages: Iodinated contrast media and related supply information. FDA. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
